|
Klinefelter Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
KDM5C could play a role in the neurocognitive development of Turner and Klinefelter syndrome.
|
30811826 |
2019 |
|
Malignant neoplasm of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we reported that KDM5C was highly expressed in PCa and CRPC specimens, and the high expression promoted CRPC cell proliferation through repressing phosphatase and tensin homolog (PTEN) gene epigenetically.
|
30921702 |
2019 |
|
Klinefelter's syndrome - male with more than two X chromosomes
|
0.010 |
Biomarker
|
disease |
BEFREE |
KDM5C could play a role in the neurocognitive development of Turner and Klinefelter syndrome.
|
30811826 |
2019 |
|
Prostate carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we reported that KDM5C was highly expressed in PCa and CRPC specimens, and the high expression promoted CRPC cell proliferation through repressing phosphatase and tensin homolog (PTEN) gene epigenetically.
|
30921702 |
2019 |
|
Malignant tumor of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
KDM5c expression upregulation in colon cancer cells had significantly reduced L-OHP and CPT-11½ inhibitory concentrations (IC50 s) and decreased the ABCC1mRNA and protein expression.
|
30257334 |
2018 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We also identified two genes significantly associated with melanoma metastasis to the regional lymph nodes (PIK3CG and IL2RA), and two genes significantly associated with sex (KDM5C and KDM6A).
|
29975213 |
2018 |
|
Colon Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
KDM5c expression upregulation in colon cancer cells had significantly reduced L-OHP and CPT-11½ inhibitory concentrations (IC50 s) and decreased the ABCC1mRNA and protein expression.
|
30257334 |
2018 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
Contrarily, RNA interference targeting KDM5C in gastric cancer cells significantly decreased the proliferation and invasive potential of cells.
|
26858085 |
2017 |
|
Refractory cancer
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The KDM5C is a histone demethylase that promotes cancer cell growth and is enriched in drug-resistant cancer cells.
|
26858085 |
2017 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Contrarily, RNA interference targeting KDM5C in gastric cancer cells significantly decreased the proliferation and invasive potential of cells.
|
26858085 |
2017 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We propose that RACK7/KDM5C functions as an enhancer "brake" to ensure appropriate enhancer activity, which, when compromised, could contribute to tumorigenesis.
|
27058665 |
2016 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Silencing JARID1C in breast cancer cells could inhibit cell migration and invasion.
|
26182878 |
2015 |
|
Cerebral Palsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ten de novo mutations in three previously identified disease genes (TUBA1A (n=2), SCN8A (n=1) and KDM5C (n=1)) and in six novel candidate CP genes (AGAP1, JHDM1D, MAST1, NAA35, RFX2 and WIPI2) were predicted to be potentially pathogenic for CP.
|
25666757 |
2015 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Silencing JARID1C in breast cancer cells could inhibit cell migration and invasion.
|
26182878 |
2015 |
|
Malignant neoplasm of kidney
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Together, these data suggest that inactivation of JARID1C in renal cancer leads to heterochromatin disruption, genomic rearrangement, and aggressive ccRCCs.
|
26551685 |
2015 |
|
Renal carcinoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Together, these data suggest that inactivation of JARID1C in renal cancer leads to heterochromatin disruption, genomic rearrangement, and aggressive ccRCCs.
|
26551685 |
2015 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
KDM5C has been proposed as an oncogene in many types of tumors; however, its role and underlying mechanisms in HCC remain unclear.
|
26503415 |
2015 |
|
Huntington Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, reduction of SMCX/Jarid1c in primary neurons from BACHD mice or the single Jarid1 in a Drosophila HD model was protective.
|
23872847 |
2013 |
|
Single tumor
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Mutational intratumor heterogeneity was seen for multiple tumor-suppressor genes converging on loss of function; SETD2, PTEN, and KDM5C underwent multiple distinct and spatially separated inactivating mutations within a single tumor, suggesting convergent phenotypic evolution.
|
22397650 |
2012 |
|
Adenocarcinoma, Clear Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
A recent large-scale screen of ∼3,500 genes by PCR-based exon re-sequencing identified several new cancer genes in ccRCC including UTX (also known as KDM6A), JARID1C (also known as KDM5C) and SETD2 (ref.2).
|
21248752 |
2011 |
|
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Differences in expression profiles were also found to exist between individual breast tumors and, in some cases, were significantly associated with conventional pathological parameters and prognostic indices: tumor grade (K (lysine) acetyltransferase 5 (KAT5), HDAC1, KDM4A, SUV39H1 and KDM6A)); TNM stage (SUV39H1, K (lysine) acetyltransferase 2B (KAT2B), lysine (K)-specific demethylase 1A (KDM1A), KDM4A, lysine (K)-specific demethylase 5C (KDM5C), K (lysine) acetyltransferase 8 (KAT8), HDAC5 and KAT5)); Nottingham Prognostic Index (KDM5C, myeloid/lymphoid or mixed-lineage leukemia (MLL), KAT8 and SET and MYND domain containing 3 (SMYD3)); receptor status (KAT5, SMYD3 and KDM1A); histological type (KAT5, KDM5C, KAT8, KDM4A and MLL); disease-free survival (SUV39H1, SMYD3, HDAC5, KDM6A, HDAC1, KDM1A, KDM4A, KAT8, KDM5C, KAT5 and MLL) and overall survival (KAT8).
|
22199269 |
2011 |
|
Impaired cognition
|
0.010 |
Biomarker
|
disease |
BEFREE |
The JARID1C-regulated genes SCN2A, CACNA1H, BDNF, and SLC18A1 have previously been associated with autism and cognitive dysfunction.
|
18203167 |
2008 |
|
Pervasive Development Disorder
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We describe a nondysmorphic patient with developmental delay and autism spectrum disorder who has a missense mutation in the Jumonji AT-rich interactive domain 1C (JARID1C) gene.
|
18203167 |
2008 |
|
Autism Spectrum Disorders
|
0.020 |
Biomarker
|
disease |
BEFREE |
Loss-of-function mutations in the histone demethylases KDM5A, KDM5B, or KDM5C are found in intellectual disability (ID) and autism spectrum disorders (ASD) patients.
|
30902578 |
2019 |
|
Neurodevelopmental Disorders
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Interestingly, mutations in all four genes (KDM5C, ARX, ZNF711 and PHF8) are associated with X-linked NDDs comprising intellectual disability as a core feature. in vitro analysis of the KDM5C promoter revealed that ARX and ZNF711 function as antagonist transcription factors that activate KDM5C expression and compete for the recruitment of PHF8.
|
31691806 |
2019 |